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under pin it. The developed Guideline presents the main concepts of AD technique, 
examples of materials and forms necessary for documentation and evaluation of 
visits performance, and detailed information of each stage necessary to conduct 
an AD Program.
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Zalis’ka O, Maksymovych N, Leleka M, Piniazhko O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Objectives: Reforming experience of health care in Western countries (Canada, 
USA, UK and other European countries) demonstrates the need for standardiza-
tion of medical and pharmaceutical care for population, taking into account the 
results of pharmacoeconomic analysis, it can reduce health care costs by 10-20 %.In 
Ukraine Prof. Olha Zalis’ka conducted theoretical bases and pharmacoeconomic 
analysis and creation of educational and methodical system of pharmacoeconom-
ics for pharmacists during 1999-2003. MethOds: From 2003 the study of discipline 
“Pharmacoeconomics” was included in curriculum of pharmacists on specialty 
“Pharmacy” and “Clinical Pharmacy” and for postgraduate training of pharmacists 
in the specialty “Economy and management of pharmacy “ and “General pharmacy 
“in Ukraine. Results: Zalis’ka Olha defended doctoral thesis “The theoretical basis 
and practical use of Pharmacoeconomics in Ukraine “ in 2004. It was published 
5 manuals “Pharmacoeconomics” (2000), “The Bases of Pharmacoenomics (2002), 
2007, 2014, which approved by Ministry of Health and Ministry of Education and 
Science of Ukraine for using of 20 pharmaceutical faculties of medical universities.
In 2008 we created ISPOR Ukraine Chapter at the Danylo Halytsky Lviv National 
Medical University (www.ispor.org / local_chapter / Ukraine) . USPOR develops and 
implements the theoretical, practical and educational areas of pharmacoeconom-
ics in Ukraine. To spread knowledge and increase access of local experts set up 
special website in ukrainian (www.uspor.org.ua), which presents the main domes-
tic results. In the postgraduate training of pharmacists we use distance learning 
program (IDL), which are available in Ukrainian. cOnclusiOns: We implemented 
the pharmacoeconomics in requirements of the “Concept of Pharmaceutical Sector 
of Health during 2011-2020”, which claim the use of pharmacoeconomics methods 
in governmental programs, providing formulary system for in-patients.We work in 
MoH Commission of Ukraine which integrates the results of pharmacoeconomic 
studies into practice to determine the list of medicines for state programs for social 
health insurance.
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Objectives: To reliably and quantitatively benchmark Health Technology 
Assessment (HTA) agencies using a single global benchmarking sys-
tem. MethOds: Literature search was conducted to identify surveys or reports 
evaluating different HTA agencies on a common scale. Using published literature, 
attributes deemed crucial for benchmarking HTA agencies were identified. In col-
laboration with clinical and actuarial experts, we developed a Likert scale to serve 
the basis for comparing key attributes of HTA submission process, i.e. pharma-
coeconomic, pricing, evidence, and general submission requirements. Results: 
Few publications have benchmarked HTA agencies against good practice and 
processes, with no published scale quantitatively assessing HTA agencies for 
attributes of submission requirements. Using identified literature and expert 
opinion, a unique Likert scale was developed with 77 questions. Each question 
were marked on a scale of 0-5, with higher score (4 or 5) indicating best practice 
or ease of accession and low score (0 or 1) indicating lack of guidance or difficulty 
in accession. As a limitation, each category may not have all options from 0-5. 
These 77 questions form 18 best practice principles, and in turn six functional 
domains, i.e. transparency, process, technical, equity, speed and implementation. 
Each domain has a unique significance: transparency - clear unbiased process, 
independent from health system; process - values innovation and prioritizes high 
value impact medicines; technical - defines and manages uncertainty to under-
stand the totality of benefit; equity - takes into account full societal benefit and 
not just health costs; speed - delivers decisions in timely manner to meet innova-
tion and timeliness; implementation - performs clear audit to ensure guidance 
is followed. cOnclusiOns: Our scale provides a new approach to benchmark 
and differentiate HTA agencies in terms of adherence to best practice and ease 
of accession. Further research is required to consider individual market needs 
driving the HTA submission standards.
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ObjectivOs: La implementación de un proceso de evaluación de tecnologías sani-
tarias (ETESA) en Chile ha visto un lento desarrollo durante los últimos 20 años. 
Recientemente el Ministerio de Salud de Chile ha elaborado una propuesta de 
institucionalización que podría acelerar la discusión social. Sin embargo, no existe 
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Objectives: Following the recent economic growth in Latin America, this analysis 
was undertaken to analyse the corresponding shift in healthcare trends, by examining 
the number of clinical trials being conducted in the region and their changing focus 
on non-communicable and communicable diseases. MethOds: ClinicalTrials.gov 
was searched in March 2015 for all trials with a study start date from January 2000 to 
December 2014 in five Latin American countries: Brazil, Chile, Colombia, Mexico and 
Peru. Studies were classified as either communicable or non-communicable according 
to the World Health Organization International Classification of Disease-10 (WHO ICD-
10), with studies that did not focus on disease or illness excluded. Results: Between 
the five selected Latin American countries there were a total of 8,847 relevant studies 
identified, 46.3% of which originated from Brazil. Over the entire time period from 
2000 to 2014, 89.3% of studies were concerning non-communicable diseases such as 
cancer, cardiovascular disease and musculoskeletal disorders, whilst 10.7% focused 
on communicable diseases. An analysis over time saw a trend of an increasing propor-
tion of trials in non-communicable diseases and a fall in the proportion of studies in 
communicable diseases. In 2000, non-communicable diseases accounted for 77.8% of 
studies, compared with 22.2% in communicable diseases, however by 2014 these per-
centages were 93.4% and 6.6%, respectively. There were 711 unique studies across the 
countries in communicable disease; 24.9% of these were in HIV/AIDs, one of the most 
deadly, infectious diseases in the region, responsible for approximately 7.2 deaths per 
100,000 people across the five selected countries. cOnclusiOns: The healthcare 
trends of Latin America appear to be changing alongside its rapid economic expan-
sion; fewer clinical trials are being carried out in preventable, infectious diseases 
more commonly associated with poor healthcare availability and substandard living 
conditions, and there is an increasing focus on non-communicable diseases such as 
neoplasms, obesity and dementias.
PHP41
governance, deciSion-making, and UniverSal HealtH coverage: 
PercePtionS from cHilean HealtH deciSion-makerS
Saavedra MA1, Greer SL2, Méndez CA1
1Universidad Austral de Chile, Valdivia, Chile, 2University of Michigan, Ann Arbor, Ann Arbor, 
MI, USA
Objectives: To explore health decision-makers’ perceptions on governance on 
decision-making process within the región de Los Ríosintegrated healthcare deliv-
ery network. MethOds: A descriptive and exploratory qualitative study base on 
in-depth interviews with health decision-makers from región de Los Ríosfrom 
June 2013 to December 2014 was conducted. A convenience sample of 11 health 
decision-makers was selected. A health decision-maker was defined as a health 
professional with a formal policy or managerial status whose primary responsibility 
would be formal leadership on decision-making (i.e. Health Service Director, and 
Hospitals Directors). The interviews were performed, recorded -previous signing of 
the informed consent- and transcript literally. The interviews’ analysis was per-
formed through the content analysis technique in its conventional approach, using 
ATLAS.ti qualitative software. Results: For the health decision-makers, a meaning 
of governance applied to health systems and services is not conceived in a technical 
approach. Moreover, governance is neither perceived as a concept related to health 
nor universal health coverage. Politics was perceived as a key issue at designing 
and implementing health decision-making processes among the Chilean health 
systems. From a governance perspective, politics of health policy is perceived as a 
strong root for health decision-making in Chile. cOnclusiOns: the Chilean case 
highlights is the paradox that establishing good enough governance to implement 
central initiatives with effective integrity might involve accountability measures 
that interfere with good administration.
PHP42
Brazilian gUideline for academic detailing: a need to imProve 
HealtH care
Costa Jd1, Almeida-Brasil CC2, Lemos LL1, Gomes RM1, Acurcio FA1, Álvares J2,  
Guerra Júnior AA1
1CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal 
University of Minas Gerais, Belo Horizonte, Brazil
Objectives: To develop a Brazilian Guideline on Academic Detailing (AD) – 
educational outreach visits to prescribers. The overall aim is to enhance the 
rational use of medicines and devices provided by the Brazilian National Health 
System (SUS). MethOds: This document was based on an extensive search of 
the literature, the AD experience of international organizations and the expe-
rience of a pilot project conducted by the SUS Collaborating Centre in Belo 
Horizonte, Brazil. A team of 15 researches, including facilitators and coordina-
tors of AD Programs participated in the development of this Guideline. Results: 
The Guideline provides an overview of the AD service that should be per-
formed by a qualified and trained health professional (facilitator). To develop 
an AD Program a technical team composed of specialists on the subject to be 
addressed, researchers and interns should be formed. It is recommended that 
at least one coordinator manage the process, orient staff members, and conduct 
the training of facilitators. The process to develop and conduct an AD Program 
involves ten stages. Stage 1: Prospection and identification of problems; Stage 2: 
Definition of the AD purpose; Stage 3: Budget estimate, elaboration of schedule and 
technical team designation; Stage 4: Elaboration and purchase of the support mate-
rial; Stage 5: Identification of prescribers and organization of visitation goals; Stage 6: 
Recruitment of facilitators and workshop training; Stage 7: Prescribers’ visiting 
for AD; Stage 8: Release of the support material; Stage 9: Evaluation of results; 
Stage 10: Release of the results. cOnclusiOns: A national Guideline is neces-
sary to ensure the quality of AD service and the processes and outcomes that 
